OvaGene Licenses miRNA Technology from Moffitt for Drug Response Assays | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OvaGene Oncology has completed a licensing and collaboration agreement with the Moffitt Cancer Center to develop and commercialize proprietary microRNA assays to predict drug response for currently used cancer drugs, the Irvine, Calif.-based molecular diagnostics firm announced on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.